<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7307812\results\search\testTrace\results.xml">
  <result pre="challenge we bring to the forefront the options for medical" exact="treatment" post="and summarize SARS-CoV2 structure and functions, immune responses and"/>
  <result pre="In mild infections (sore throat, cough) we advocate prompt local" exact="treatment" post="for the naso-pharynx (inhalations; aerosols; nebulizers); for moderate to"/>
  <result pre="antiviral drugs; iii) The combination of arginine-ascorbate. SARS-CoV2 COVID-19 antiviral" exact="treatment" post="ARDS sepsis arginine ascorbate coronavirus 1. Clinical aspects of"/>
  <result pre="identified 3 biological markers associated with the severity of the" exact="infection" post="and progression to ARDS and death: i) neutrophilia; ii)"/>
  <result pre="approved remdesivir (GS5734 - an RNA polymerase inhibitor) as specific" exact="treatment" post="for COVID-19; different protocols use chloroquine (500 mg q"/>
  <result pre="healing (fibrosis) in lungs. A unique molecular signature of lethal" exact="infection" post="with another respiratory virus (PR8, an influenza virus) showed"/>
  <result pre="of lethal infection. Comparing viral replication in non-lethal vs. lethal" exact="infection" post="they had similar viral replication rates, but the lethal"/>
  <result pre="infection they had similar viral replication rates, but the lethal" exact="infection" post="had increased viral titers in the lungs, and also"/>
  <result pre="variety of therapeutic contexts (27). Efficacy of Dapsone in the" exact="treatment" post="of Pneumocystis pneumonia suggests it will penetrate the lung"/>
  <result pre="fusion process used by SARS-CoV involves endosomal membranes and a" exact="treatment" post="which blocks only the cell surface proteases or the"/>
  <result pre="the host immune system, and because the success of viral" exact="infection" post="depends on the impairment of the host antiviral response,"/>
  <result pre="stability and translation, particle and budding (50). Molecules involved in" exact="virus detection" post="in the cytoplasm of host cells are: the retinoic"/>
  <result pre="and translation, particle and budding (50). Molecules involved in virus" exact="detection" post="in the cytoplasm of host cells are: the retinoic"/>
  <result pre="host cell translation and helps activate the NF-ÎºB. Early in" exact="infection" post="the antiviral response is driven by the peroxisomal MAVS,"/>
  <result pre="(50): i) after transcription the coronaviral dsRNA is protected from" exact="detection" post="by storage in double-membrane vesicles; ii) M protein of"/>
  <result pre="proteases (68), more information is given in Table III. Local" exact="treatment" post="and IFNs. Based on the observation that the host"/>
  <result pre="volume of 20-30 ml) and can act early in COV" exact="infection" post="during the viral fusion process, inhibiting the binding of"/>
  <result pre="from the binding motif of the S protein has inhibited" exact="infection" post="by many human coronaviruses (46); its administration in mice"/>
  <result pre="neutrophilia and lymphopenia observed in severe COVID-19 patients, fatal SARS" exact="infection" post="is associated with high IFN and ISGs expression and"/>
  <result pre="IFN-Î±/Î² receptor (IFNAR) receptor ablation or neutrophil depletion avoided lethal" exact="infection" post="but did not affect the viral load. TNF inhibition"/>
  <result pre="SARS infection, IFN-Î³ presence is associated with viral clearance and" exact="infection" post="resolution; IFN-Î³ is synthesized mainly by activated T cells"/>
  <result pre="developed pulmonary fibrosis (83). The modifications induced by the SARS-Cov" exact="infection" post="in host cells were also investigated via a library"/>
  <result pre="complex lipids (inositol phosphate, nicotinate, nicotinamide), intermediates needed in SARS-CoV" exact="infection" post="and probably linked to prenylation. The strongest proviral activation"/>
  <result pre="through degradation of tryptophan and kynurenines; its role in SARS-CoV2" exact="infection" post="was not explored but likely is important (86). Activation"/>
  <result pre="an IDO inhibitor; the role of IDO in the SARS-CoV2" exact="infection" post="and its immune evasion has not yet been explored."/>
  <result pre="been explored. The data above confirm that in severe CoV" exact="infection" post="the host immune system is mounting an imbalanced response"/>
  <result pre="the host immune system is mounting an imbalanced response to" exact="infection" post="which powerfully favors neutrophils/macrophages and inhibits the adaptive cellular"/>
  <result pre="to the lack of activation in the early stage of" exact="infection" post="of the peroxisomal MAVS necessary for early IFN production"/>
  <result pre="(n=168) evaluated the influence of ACE I/D polymorphism on SARS-CoV" exact="infection" post="susceptibility and development of ARDS in a Chinese population"/>
  <result pre="between the frequency of the D allele and presence of" exact="infection" post="or severe disease; the only factors associated with requirement"/>
  <result pre="and pulmonary fibrosis; ACE2 expression increases after IFN-I administration. SARS-CoV" exact="infection" post="produces a rapid downregulation of ACE2 expression at cell"/>
  <result pre="hypertensive patients with a history of angio-oedema during ACE inhibitor" exact="treatment" post="(120); the aminopeptidase N is also a receptor for"/>
  <result pre="of NOS in mice resulted in conversion of a resolving" exact="infection" post="by the ectromelia virus into fulminant mousepox (126). NO"/>
  <result pre="arginine availability is a critical factor for host resistance to" exact="infection" post="(122). NO can pass through membranes, unlike complement and"/>
  <result pre="anti-NOS and other IDO activities. In the case of SARS-CoV2" exact="infection" post="which directly antagonizes NO production, arginine provides both the"/>
  <result pre="more of: trauma, cancer, chronic infection, liver necrosis, pulmonary hypertension;" exact="treatment" post="for ADS include L-arginine and the arginase inhibitors N-hydroxy-arginine"/>
  <result pre="and pathways are involved in the immune response in viral" exact="infection" post="and individual variability can also have an important role."/>
  <result pre="least 3 times a day each. We have found this" exact="treatment" post="effective in many types of viral infections, including common"/>
  <result pre="and beneficial in critically ill patients, contributing to resolution of" exact="infection" post="and improving morbidity and mortality (158). Adding ascorbate makes"/>
  <result pre="limiting exposure to the pathogen in vulnerable populations and also" exact="testing" post="and treating early, as soon as possible after respiratory"/>
  <result pre="treating early, as soon as possible after respiratory symptoms. After" exact="infection" post="and respiratory symptoms, prompt local treatment is very important:"/>
  <result pre="after respiratory symptoms. After infection and respiratory symptoms, prompt local" exact="treatment" post="is very important: aerosol inhalation, nasal drops, throat sprays"/>
  <result pre="decrease inflammation. We propose arginine-ascorbate as the mainstay of antiviral" exact="treatment" post="for SARS-CoV2 and other coronaviruses, administered from the initial"/>
  <result pre="SARS-CoV2 and other coronaviruses, administered from the initial signs of" exact="infection" post="until its resolution. As much as NSAIDs (non-steroidal antiinflammatory"/>
  <result pre="be elevated in elderly patients, and further elevated by SARS-CoV" exact="infection" post="and in more severe forms of COVID-19 (73); however"/>
  <result pre="risk for progression to severe forms early on during CoV" exact="infection" post="is important for prompt individual treatment and medical resource"/>
  <result pre="early on during CoV infection is important for prompt individual" exact="treatment" post="and medical resource management, and also to avoid imposing"/>
  <result pre="or can be treated outside hospital; this may allow shifting" exact="isolation" post="measures from whole populations to truly at-risk populations (168)."/>
  <result pre="at-risk - elderly and with chronic co-morbidities, evaluation with different" exact="testing" post="panels can reasonably assess their risk for severe COVID19,"/>
  <result pre="CXCl-2 (106). Another approach to risk evaluation of severe COV" exact="infection" post="is measuring the high-sensitivity cardiac troponin (hs-cTnT), shown with"/>
  <result pre="replication in cell cultureAntimicrob Agents Chemother5848754884201410.1128/AAC.03011-1424841269 18CascellaMRajnikMCuomoADulebohnSCDi NapoliRFeatures, evaluation and" exact="treatment" post="coronavirus (COVID-19)StatPearls [Internet]Treasure Island (FL)StatPearls Publishing20201https://www.ncbi.nlm.nih.gov/books/NBK554776 19NeaguMBostanMConstantinCProtein microarray technology:"/>
  <result pre="syndrome: Prognostic indicatorsAm J Respir Crit Care Med1547681199610.1164/ajrccm.154.1.86807038680703 27KastREDapsone as" exact="treatment" post="adjunct in ARDSExp Lung Res46157161202010.1080/01902148.2020.175326632286085 28ColemanMDRhodesLEScottAKVerbovJLFriedmannPSBreckenridgeAMParkBKThe use of cimetidine"/>
  <result pre="in CoV of the same cladeAntiviral Res176104742202010.1016/j.antiviral.2020.10474232057769 44KawaseMShiratoKvan der HoekLTaguchiFMatsuyamaSSimultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
  <result pre="clinically proven protease inhibitorCell181271280.e8202010.1016/j.cell.2020.02.05232142651 46XiaSLiuMWangCXuWLanQFengSQiFBaoLDuLLiuSet al.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
  <result pre="J Immunol47615628201710.1002/eji.20164648428295214 58VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGSeidahNGNicholSTChloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J269200510.1186/1743-422X-2-6916115318 59SamarthSMcGregorKEnergetics based modeling of hydroxychloroquine and"/>
  <result pre="entry inhibitors by drug repurposing using in silico structure-based virtual" exact="screening" post="approachChemRxiv202010.26434/chemrxiv.12005988 63FaragAWangPBoysINEitsonJOhlsonMBFanWMcDougalMBAhmedMSchogginsJWIdentification of atovaquone, quabain and mebendazole as FDA"/>
  <result pre="novel corona virus (Covid-19): Molecular docking studyChemRxiv2020Preprint. 10.26434/chemrxiv.12055716.v1 69PendyalaBPatrasAIn silico" exact="screening" post="of food bioactive compounds to predict potential inhibitors of"/>
  <result pre="10.26434/chemrxiv.11987475.v1 71BoschBJMartinaBEEVan Der ZeeRLepaultJHaijemaBJVersluisCHeckAJDe GrootROsterhausADRottierPJSevere acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="inhibition using spike protein heptad repeat-derived peptidesProc Natl Acad"/>
  <result pre="and enhanced by dendritic cell transfer through DC-SIGNJ Virol7856425650200410.1128/JVI.78.11.5642-5650.200415140961 73ZhaoJWohlford-LenaneCZhaoJFlemingELaneTEMcCrayPBJrPerlmanSIntranasal" exact="treatment" post="with poly(Iâ€¢C) protects aged mice from lethal respiratory virus"/>
  <result pre="accessory protein vpu downregulates peroxisome biogenesisMBio1111202010.1128/mBio.03395-19 91ZhengCSuCHerpes simplex virus 1" exact="infection" post="dampens the immediate early antiviral innate immunity signaling from"/>
  <result pre="commander in innate immune responsesSci Signal3pe27201010.1126/scisignal.3135pe2720716762 123KeyaertsEVijgenLChenLMaesPHedenstiernaGVan RanstMInhibition of SARS-coronavirus" exact="infection" post="in vitro by S-nitroso-N- acetylpenicillamine, a nitric oxide donor"/>
  <result pre="during severe acute respiratory syndrome coronavirus infectionJ Virol861333413349201210.1128/JVI.01689-1223015710 149BlockGJensenCDDalviTBNorkusEPHudesMCrawfordPBHollandNFungEBSchumacherLHarmatzPVitamin C" exact="treatment" post="reduces elevated C-reactive proteinFree Radic Biol Med467077200910.1016/j.freeradbiomed.2008.09.03018952164 150KimWYJungJWChoiJCShinJWKimJYSubphenotypes in"/>
  <result pre="(Ref.) Viral molecule inhibited; mechanism Method and/or software used for" exact="testing" post="FDA approved drugs Hydroxychloroquine and azithromycin (59) Spike (S)"/>
  <result pre="ACE2 receptor protein of host cells binding site High-throughput virtual" exact="screening" post="used to investigate LOPAC library drugs KT185, KT203 GSK1838705A,"/>
  <result pre="protease with the ligands and the AutoDock Vina tool for" exact="testing" post="the cloperastine (-10.1) nicer- unliganded active site docking on"/>
  <result pre="(Ref.) Viral molecule inhibited; mechanism Method and/or software used for" exact="testing" post="Anisotine and vasicoline of Justicia adhatoda (65) Protease; RNA"/>
 </snippets>
</snippetsTree>
